Replies to post #156335 on Vivos Inc (RDGL)

[SC8]

Again, per financial reports to date, RDGL is forecasting burn rate going to $5 million per year post IDE. That figure will only go up per current inflation. Beyond human trials, IsoPet expenditures must greatly increase to have any hope of profitability. Raising that kind of $ isn't an issue with IDE in hand, or even with a hedge offering during the 30 day consideration period. Hence why everything depends on IDE submission now.

[anderson800]

That looks pretty reasonable. Once you get positive results and you go multicenter then the costs will begin to shoot up, but they could have a buyout offer by that point.